+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sacubitril Valsartan Sodium Drugs Market by Type, Strength, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sacubitril Valsartan Sodium Drugs Market by Type, Strength, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Sacubitril Valsartan Sodium Drugs Market by Type, Strength, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6079054
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Understanding the Sacubitril Valsartan Sodium Landscape

The treatment landscape for heart failure has been fundamentally altered with the introduction of sacubitril valsartan sodium, marking a paradigm shift in disease management and patient outcomes. This combination therapy, which leverages neprilysin inhibition alongside angiotensin receptor blockade, has set new standards for efficacy and tolerability, prompting healthcare professionals to reevaluate traditional protocols. As regulatory approvals expand and clinical guidelines evolve, stakeholders across the value chain-from pharmaceutical developers to payers-are seeking clarity on market dynamics and emerging opportunities.

This report delves into the critical drivers transforming the sacubitril valsartan sodium market, examining innovation pipelines, competitive entries, and evolving care models. By synthesizing primary interviews with leading cardiologists, supply-chain executives, and policy experts, alongside rigorous secondary research, we deliver a nuanced perspective on how this therapy is reshaping patient care. Through systematic analysis, we highlight the intersection of clinical outcomes, pricing pressures, and distribution strategies that will define the next phase of growth. Readers should expect a balanced, data-driven narrative that informs strategic decision-making and supports investment, commercial, and policy initiatives in this rapidly evolving segment of cardiovascular therapeutics.

Pivotal Shifts Reshaping the Sacubitril Valsartan Sodium Landscape

Rapid advances in drug development, coupled with shifting healthcare models, have converged to redefine the sacubitril valsartan sodium market. On the clinical front, real-world evidence and adaptive trials are accelerating the optimization of dosing regimens, while digital health platforms enable remote monitoring that enhances patient adherence and outcomes. Simultaneously, the entry of specialized contract development and manufacturing organizations has streamlined production, reducing time to market and fostering competitive pricing dynamics.

Innovation is not limited to formulation improvements; strategic collaborations between biotech firms and large pharmaceutical players have unlocked novel delivery systems and co-formulation approaches designed to address comorbidities in heart failure populations. Such alliances are paving the way for next-generation therapies that combine sacubitril valsartan sodium with complementary agents, broadening therapeutic scope. Moreover, value-based contracting models are gaining momentum, incentivizing outcomes over volume and aligning stakeholder interests from payers to providers. As these transformative forces gain traction, companies that proactively adapt their R&D, pricing, and distribution strategies will be best positioned to capture market share and drive sustainable growth.

Assessing the 2025 US Tariffs on Sacubitril Valsartan Sodium

The introduction of new tariff structures by the United States in 2025 has created significant headwinds for import-dependent supply chains in the sacubitril valsartan sodium market. Increased duties on active pharmaceutical ingredients sourced from key manufacturing hubs have translated into elevated production costs, which suppliers have sought to mitigate through supply-chain diversification and renegotiation of long-term procurement contracts. While some manufacturers have absorbed a portion of these additional expenses to maintain competitive pricing, others have passed costs to distributors, triggering pricing pressures at the point of sale.

To navigate this landscape, several stakeholders have expedited nearshoring initiatives, establishing API production facilities within tariff-exempt zones or under favorable trade agreements. Concurrently, parallel trade and strategic stockpiling have emerged as tactical responses to shield inventory from sudden cost escalations. Regulatory bodies have also taken note, with policy revisions aimed at preserving access while balancing domestic industry protection. Although the cumulative impact of these measures remains fluid, proactive risk management and agile sourcing strategies will be critical to sustaining supply resilience and margin stability through the remainder of the tariff cycle.

Unveiling Core Segmentation Dynamics

When analyzed through the lens of type differentiation, brand offerings continue to command a premium position, driven by clinician familiarity and established efficacy profiles, while generic entrants are rapidly capturing volume through cost advantages and formulary inclusion. Strength segmentation reveals that the 24-26 mg dosage segment is favored for treatment initiation and dose escalation, the 49-51 mg range represents the core volume cohort balancing efficacy with tolerability, and the 97-103 mg concentration is reserved for patients requiring aggressive maintenance therapy in advanced heart failure.

End-user patterns demonstrate that clinics serve as pivotal points for early diagnosis and prescription initiation, home care services facilitate long-term patient management and adherence support, and hospitals remain indispensable for acute intervention and titration supervision. Distribution channel analysis indicates that hospital pharmacies secure high-value contracts centered on inpatient care, online pharmacies are driving incremental growth via direct-to-patient fulfillment models, and retail outlets sustain widespread accessibility through community checkpoints. These segmentation insights collectively inform targeted commercialization strategies, enabling stakeholders to align portfolio priorities with evolving demand across each clinical and distribution dimension.

Navigating Regional Variances and Growth Drivers

Across the Americas, market maturity is characterized by well-established reimbursement frameworks, high patient awareness, and robust clinical adoption, though pricing scrutiny and value-based contracting are intensifying. In Europe, Middle East & Africa, variable regulatory landscapes and heterogeneous healthcare infrastructures necessitate tailored market access approaches; Western Europe leads in uptake driven by national guidelines, the Middle East is emerging as a growth corridor with rising cardiovascular disease prevalence, and Africa presents untapped potential hindered by distribution bottlenecks.

In Asia-Pacific, soaring incidence of heart failure coupled with expanding healthcare investment fuel demand, particularly in China and India, where local manufacturing partnerships are accelerating supply. Nations such as Japan and Australia continue to adopt novel therapies rapidly under progressive regulatory regimes, creating reference benchmarks for neighboring markets. By understanding these regional nuances-from payer structures to patient demographics-industry participants can prioritize resource allocation, optimize launch sequencing, and design region-specific education programs that resonate with local stakeholders.

Competitive Footprint of Leading Industry Stakeholders

Key players in the sacubitril valsartan sodium arena have adopted distinct strategies to fortify their market positions. Innovator companies are leveraging robust clinical trial data and brand legacy to reinforce prescriber loyalty and negotiate value-based agreements. Concurrently, leading generic manufacturers are executing aggressive cost-optimization and biosimilar development plans, supported by strategic alliances with contract manufacturing organizations to scale supply and reduce time to market.

Partnership models between specialty biotech firms and global distribution networks have also gained prominence, facilitating access to previously underpenetrated regions while sharing risk across stakeholders. Additionally, several emerging players are focusing on niche formulations and fixed-dose combinations to differentiate their offerings. Intellectual property portfolios, licensing arrangements, and patent challenges are shaping competitive dynamics, with litigation and settlements influencing generic entry timelines. The competitive landscape is expected to intensify as additional biosimilar candidates progress through development, underscoring the need for continuous monitoring of pipeline advances and market entry barriers.

Strategic Actions for Market Leadership

To capitalize on the evolving sacubitril valsartan sodium market, industry leaders should prioritize investment in next-generation formulations that improve patient adherence and broaden therapeutic scope. Strengthened partnerships with healthcare providers and payers will enable shared risk models, aligning pricing structures with outcomes and driving formulary inclusion. Companies can further enhance resilience by diversifying supply chains to mitigate geopolitical and tariff vulnerabilities, establishing secondary sourcing agreements, and exploring strategic nearshoring opportunities.

In parallel, targeted educational initiatives should be deployed to elevate clinician and patient awareness, leveraging digital platforms and real-world evidence to demonstrate value. A focused approach to emerging markets-grounded in local partnerships and tailored market access strategies-will accelerate growth in high-potential regions. Finally, continuous horizon scanning of competitive pipelines and regulatory shifts will equip leadership teams with the foresight to adapt commercialization plans dynamically; this agility will be a critical differentiator in capturing market share and sustaining long-term profitability.

Rigorous Research Framework and Methodology

This analysis is underpinned by an exhaustive research framework that integrates primary and secondary data sources. Primary inputs were obtained through structured interviews and surveys with cardiologists, supply-chain executives, payers, and regulatory experts across key geographies. These insights were triangulated against peer-reviewed literature, patent filings, company disclosures, and proprietary industry databases to ensure comprehensive coverage of clinical, commercial, and regulatory dimensions.

Secondary research encompassed market intelligence reports, healthcare policy analyses, and economic models to validate trends and quantify impact drivers. Data quality was assured through cross-verification protocols, involving independent audits and consistency checks. The research team employed thematic coding to identify emerging patterns, while quantitative analyses leveraged descriptive and inferential statistics to assess segmentation performance and regional variances. This rigorous methodology provides a robust foundation for the strategic insights and recommendations presented throughout the report.

Consolidating Key Learnings and Implications

In summary, the sacubitril valsartan sodium market stands at a critical juncture defined by clinical innovation, policy reforms, and shifting competitive dynamics. The integration of novel trial designs, value-based contracting, and digital health initiatives is reshaping the therapeutic paradigm. Meanwhile, emerging tariff regimes and supply-chain strategies are recalibrating cost structures, necessitating agile operational models.

Segmentation analysis highlights the nuanced interplay between product type, dosage strengths, end-user settings, and distribution channels, guiding targeted commercialization. Regional insights underscore the need for customized market access approaches that reflect local regulatory and economic realities. Competitive profiling reveals an intensifying landscape, where strategic alliances and differentiated portfolios will determine leadership trajectories.

By synthesizing these multifaceted insights, this report equips decision-makers with the strategic clarity required to navigate complexities, capitalize on growth opportunities, and sustain long-term value. Stakeholders are encouraged to integrate these findings into their strategic planning processes to reinforce market resilience and drive innovation in heart failure management.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Type
    • Brand
    • Generic
  • Strength
    • 24 26 Mg
    • 49 51 Mg
    • 97 103 Mg
  • End User
    • Clinics
    • Home Care
    • Hospitals
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc
  • Zydus Lifesciences Ltd
  • Torrent Pharmaceuticals Ltd
  • Aurobindo Pharma Ltd
  • Alembic Pharmaceuticals Ltd
  • Lupin Ltd
  • Hetero Labs Limited
  • Dr. Reddy’s Laboratories Ltd

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sacubitril Valsartan Sodium Drugs Market, by Indication
8.1. Introduction
8.2. Heart Failure
8.2.1. Acute Heart Failure
8.2.2. Chronic Heart Failure
8.3. Hypertension
8.3.1. Primary Hypertension
8.3.2. Secondary Hypertension
9. Sacubitril Valsartan Sodium Drugs Market, by Dosage Form
9.1. Introduction
9.2. Capsule
9.2.1. Hard Capsule
9.2.2. Liquid-Filled
9.3. Tablet
9.3.1. Film-Coated Tablets
9.3.2. Immediate Release
10. Sacubitril Valsartan Sodium Drugs Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.2.1. Middle-Aged Adults
10.2.2. Young Adults
10.3. Elderly
10.3.1. Very Elderly
10.3.2. Young Elderly
10.4. Pediatric
10.4.1. Adolescents
10.4.2. Children
10.4.3. Infants
11. Sacubitril Valsartan Sodium Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. General Clinics
11.2.2. Specialty Clinics
11.3. Hospitals
11.3.1. Private Hospitals
11.3.2. Public Hospitals
11.4. Online Pharmacies
11.4.1. E-Commerce Platforms
11.4.2. Telemedicine Services
11.5. Retail Pharmacies
11.5.1. Chain Pharmacies
11.5.2. Independent Pharmacies
12. Sacubitril Valsartan Sodium Drugs Market, by Condition Severity
12.1. Introduction
12.2. Mild
12.2.1. Asymptomatic
12.2.2. Mild Symptoms
12.3. Moderate
12.3.1. Ambulatory
12.3.2. Diagnostic Symptoms
12.4. Severe
12.4.1. Advanced Care Needed
12.4.2. Hospitalized
13. Sacubitril Valsartan Sodium Drugs Market, by Marketing Channel
13.1. Introduction
13.2. Direct Marketing
13.2.1. Doctor Recommendations
13.2.2. Pharmaceutical Representatives
13.3. Indirect Marketing
13.3.1. Healthcare Conferences
13.3.2. Television & Online Ads
14. Sacubitril Valsartan Sodium Drugs Market, by Packaging
14.1. Introduction
14.2. Blister Packs
14.2.1. Single Blister
14.3. Bottles
14.3.1. Glass Bottles
14.3.2. Plastic Bottles
15. Americas Sacubitril Valsartan Sodium Drugs Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Sacubitril Valsartan Sodium Drugs Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Sacubitril Valsartan Sodium Drugs Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories Inc.
18.3.2. Alkem Laboratories Ltd.
18.3.3. Cipla Limited
18.3.4. Everolimus Holdings Ltd.
18.3.5. Glenmark Pharmaceuticals Ltd.
18.3.6. Hetero Labs Limited
18.3.7. Hisun Pharmaceutical Co. Ltd.
18.3.8. Lupin Pharmaceuticals, Inc.
18.3.9. Novartis International AG
18.3.10. Pfizer Inc.
18.3.11. Shanghai Pharmacare Ltd.
18.3.12. Sun Pharmaceutical Industries Ltd.
18.3.13. Teva Pharmaceutical Industries Ltd.
18.3.14. Torrent Pharmaceuticals Ltd.
18.3.15. Zydus Cadila Healthcare Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. SACUBITRIL VALSARTAN SODIUM DRUGS MARKET MULTI-CURRENCY
FIGURE 2. SACUBITRIL VALSARTAN SODIUM DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. SACUBITRIL VALSARTAN SODIUM DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CONDITION SEVERITY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CONDITION SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MARKETING CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MARKETING CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PACKAGING, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PACKAGING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. SACUBITRIL VALSARTAN SODIUM DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ACUTE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PRIMARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SECONDARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HARD CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY LIQUID-FILLED, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY FILM-COATED TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY VERY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY YOUNG ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TELEMEDICINE SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CONDITION SEVERITY, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ASYMPTOMATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MILD SYMPTOMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MILD, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY AMBULATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DIAGNOSTIC SYMPTOMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MODERATE, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADVANCED CARE NEEDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MARKETING CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DIRECT MARKETING, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOCTOR RECOMMENDATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PHARMACEUTICAL REPRESENTATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDIRECT MARKETING, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEALTHCARE CONFERENCES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TELEVISION & ONLINE ADS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BLISTER PACKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SINGLE BLISTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BLISTER PACKS, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BOTTLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY GLASS BOTTLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PLASTIC BOTTLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BOTTLES, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CONDITION SEVERITY, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MILD, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MODERATE, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MARKETING CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BLISTER PACKS, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BOTTLES, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CONDITION SEVERITY, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MILD, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MODERATE, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MARKETING CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BLISTER PACKS, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BOTTLES, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CONDITION SEVERITY, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MILD, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MODERATE, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MARKETING CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BLISTER PACKS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BOTTLES, 2018-2030 (USD MILLION)
TABLE 161. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 163. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 164. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 165. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 166. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 167. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 169. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 170. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 171. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 173. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 174. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 175. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 176. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CONDITION SEVERITY, 2018-2030 (USD MILLION)
TABLE 177. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MILD, 2018-2030 (USD MILLION)
TABLE 178. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MODERATE, 2018-2030 (USD MILLION)
TABLE 179. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 180. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MARKETING CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 182. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 183. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 184. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BLISTER PACKS, 2018-2030 (USD MILLION)
TABLE 185. CANADA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BOTTLES, 2018-2030 (USD MILLION)
TABLE 186. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 188. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 189. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 190. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 191. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 192. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 194. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 195. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 196. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 198. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 199. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 200. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 201. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CONDITION SEVERITY, 2018-2030 (USD MILLION)
TABLE 202. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MILD, 2018-2030 (USD MILLION)
TABLE 203. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MODERATE, 2018-2030 (USD MILLION)
TABLE 204. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 205. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MARKETING CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 207. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 208. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 209. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BLISTER PACKS, 2018-2030 (USD MILLION)
TABLE 210. MEXICO SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BOTTLES, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CONDITION SEVERITY, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MILD, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MODERATE, 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MARKETING CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 232. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 233. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 234. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BLISTER PACKS, 2018-2030 (USD MILLION)
TABLE 235. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BOTTLES, 2018-2030 (USD MILLION)
TABLE 236. UNITED STATES SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CONDITION SEVERITY, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MILD, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MODERATE, 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MARKETING CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BLISTER PACKS, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BOTTLES, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 278. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CONDITION SEVERITY, 2018-2030 (USD MILLION)
TABLE 279. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MILD, 2018-2030 (USD MILLION)
TABLE 280. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MODERATE, 2018-2030 (USD MILLION)
TABLE 281. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY SEVERE, 2018-2030 (USD MILLION)
TABLE 282. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY MARKETING CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 284. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDIRECT MARKETING, 2018-2030 (USD MILLION)
TABLE 285. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
TABLE 286. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BLISTER PACKS, 2018-2030 (USD MILLION)
TABLE 287. AUSTRALIA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY BOTTLES, 2018-2030 (USD MILLION)
TABLE 288. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 289. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 290. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
TABLE 291. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 292. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 293. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 294. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 295. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 296. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 297. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 298. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 300. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 301. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 302. CHINA SACUBITRIL VALSARTAN SODIUM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 303. CHINA SACUBITRI

Companies Mentioned

The companies profiled in this Sacubitril Valsartan Sodium Drugs market report include:
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc
  • Zydus Lifesciences Ltd
  • Torrent Pharmaceuticals Ltd
  • Aurobindo Pharma Ltd
  • Alembic Pharmaceuticals Ltd
  • Lupin Ltd
  • Hetero Labs Limited
  • Dr. Reddy’s Laboratories Ltd

Methodology

Loading
LOADING...

Related Topics

Related Reports

Sacubitril Valsartan Sodium Tablets Market by Distribution Channel, End-User, Product Type, Strength, Dosage Form - Global Forecast to 2030 - Product Image

Sacubitril Valsartan Sodium Tablets Market by Distribution Channel, End-User, Product Type, Strength, Dosage Form - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Valsartan (CAS 137862-53-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Valsartan (CAS 137862-53-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Angiotensin Receptor Blockers (ARBs) Market Report 2025 - Product Image

Angiotensin Receptor Blockers (ARBs) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 331 Pages
  • Global
From
Heart Failure Drugs - Global Strategic Business Report - Product Image

Heart Failure Drugs - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.